Descripción de la empresa
Jupiter Neurosciences, Inc. operates as a clinical stage research and development pharmaceutical entity focused on advancing resveratrol platform products designed to treat neuroinflammation. The company functions within the broader healthcare sector, specifically targeting the biotechnology industry, which implies a high-risk, high-reward environment centered on developing novel therapies for rare and complex diseases. As of the latest available data, Jupiter Neurosciences holds a market capitalization of $12.70M, with reported annual revenue (TTM) of $21,796 and an undisclosed employee count. These financial metrics indicate that the company is a micro-cap entity with extremely limited revenue generation relative to its valuation, suggesting it is in an early-stage development phase where capital preservation and successful clinical trial execution are the primary drivers of value rather than current profitability or scale.
Salud financiera
The financial statements for Jupiter Neurosciences, Inc. reveal a revenue figure of $21,796 over the trailing twelve months, accompanied by a net income of $-8,644,897 and an unavailable EBITDA metric. The substantial gap between the minimal revenue and the significant net loss highlights a cost structure dominated by research and development expenses typical of clinical-stage biotechnology firms, where cash burn is necessary to advance assets through regulatory pathways. The company reports a free cash flow of $-2,314,987, indicating a continuous outflow of cash required to fund operations and trial activities, which limits immediate financial flexibility but is often standard for companies in this lifecycle. Margin analysis shows a gross margin of 0.0%, an operating margin of -12886.7%, and a profit margin of 0.0%, reflecting that the company has not yet achieved commercial scalability or cost efficiencies associated with mature pharmaceutical products. In terms of liquidity, Jupiter Neurosciences holds $3.79M in cash against $5.32M in debt, while the debt-to-equity ratio is not available; however, the cash position is insufficient to cover total debt without external financing or asset monetization. The current ratio stands at 0.65, signaling that the company's current assets are less than its current liabilities, which points to potential short-term liquidity challenges. Additionally, the return on equity is -738.8% and the return on assets is -94.6%, metrics that mathematically demonstrate the company is currently destroying shareholder value and utilizing assets inefficiently due to its status as a pre-revenue, loss-making entity.
Evaluación de valoración
Valuation multiples for Jupiter Neurosciences, Inc. present a complex picture, with a trailing P/E ratio (TTM) that is not available due to negative earnings and a forward P/E of 5.83. The discrepancy between the unavailable trailing P/E and the low forward P/E suggests that the market is pricing the stock based on anticipated future profitability rather than current performance, though this low multiple does not guarantee future earnings realization. The price-to-book ratio is exceptionally high at 175.00, indicating that the market values the company at a massive premium over its net book value, a scenario common in biotech stocks where the value is tied to intellectual property and pipeline potential rather than tangible assets. Alternative valuation metrics include a price-to-sales ratio of 582.60 and an EV/EBITDA that is not available, figures that suggest the market is willing to pay an enormous multiple for every dollar of sales, likely driven by the specific therapeutic potential of the JNS101 asset in Phase II trials. The stock price has fluctuated significantly over the past year, trading between a 52-week high of $3.33 and a 52-week low of $0.31. While the exact current trading price is not provided in the source data, the wide range implies high volatility, and any current price near the low end would represent a significant discount from the 52-week high, whereas a price near the high would reflect a substantial premium. The beta value is not available, preventing a direct comparison of price volatility relative to the broader market, but the wide spread between the high and low suggests intrinsic high sensitivity to market sentiment and clinical trial updates.
Growth & Income
Growth metrics for Jupiter Neurosciences, Inc. show that revenue growth year-over-year is not available and earnings growth year-over-year is also not available due to the company's recent financial history. In the absence of positive earnings, the concept of earnings growing faster or slower than revenue is not applicable, as the company is focused entirely on capitalizing its research pipeline rather than expanding profitable operations. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available cash flows and retained earnings are reinvested directly into research, development, and clinical trial costs. This reinvestment strategy is characteristic of clinical-stage biotechnology companies that prioritize advancing their drug candidates through Phase II trials for conditions like Friedreich's Ataxia over returning capital to shareholders via dividends. Consequently, the overall growth and income profile is defined by a lack of current income generation and a reliance on external capital markets to fund future growth, making the stock suitable only for investors seeking exposure to early-stage pharmaceutical innovation rather than income or immediate financial returns.